Synaptogenix (SNPX) Competitors $5.82 -0.73 (-11.08%) As of 08/29/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. MDCX, MRSN, OKUR, XCUR, EPIX, XLO, ESLA, THAR, MURA, and SCYXShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Medicus Pharma (MDCX), Mersana Therapeutics (MRSN), OnKure Therapeutics (OKUR), Exicure (XCUR), ESSA Pharma (EPIX), Xilio Therapeutics (XLO), Estrella Immunopharma (ESLA), Tharimmune (THAR), Mural Oncology (MURA), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors Medicus Pharma Mersana Therapeutics OnKure Therapeutics Exicure ESSA Pharma Xilio Therapeutics Estrella Immunopharma Tharimmune Mural Oncology SCYNEXIS Synaptogenix (NASDAQ:SNPX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do institutionals & insiders hold more shares of SNPX or MDCX? 10.3% of Synaptogenix shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 11.2% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is SNPX or MDCX more profitable? Synaptogenix's return on equity of -115.28% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -115.28% -58.31% Medicus Pharma N/A -549.30%-228.06% Which has preferable earnings & valuation, SNPX or MDCX? Medicus Pharma is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$12.77M-$10.08-0.58Medicus PharmaN/AN/A-$11.16M-$1.34-1.45 Does the media favor SNPX or MDCX? In the previous week, Medicus Pharma had 3 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Medicus Pharma and 0 mentions for Synaptogenix. Medicus Pharma's average media sentiment score of 0.47 beat Synaptogenix's score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media. Company Overall Sentiment Synaptogenix Neutral Medicus Pharma Neutral Do analysts prefer SNPX or MDCX? Medicus Pharma has a consensus price target of $23.50, suggesting a potential upside of 1,111.34%. Given Medicus Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Medicus Pharma is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 SummaryMedicus Pharma beats Synaptogenix on 9 of the 13 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.09M$3.06B$5.67B$9.84BDividend YieldN/A2.28%3.93%4.04%P/E Ratio-0.5820.9283.1926.61Price / SalesN/A200.54451.26176.46Price / CashN/A44.0537.7059.65Price / Book1.348.0710.556.59Net Income-$12.77M-$53.98M$3.27B$266.12M7 Day Performance-23.92%-0.88%0.46%0.17%1 Month Performance-15.16%6.20%5.91%3.03%1 Year Performance46.97%7.13%48.81%19.98% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenixN/A$5.82-11.1%N/A+85.4%$8.09MN/A-0.584MDCXMedicus Pharma1.5124 of 5 stars$2.04-6.0%$23.50+1,052.0%N/A$38.66MN/A-1.52N/AGap UpMRSNMersana Therapeutics4.1028 of 5 stars$7.65flat$56.60+639.9%-80.7%$38.18M$40.50M-0.52150OKUROnKure Therapeutics2.8581 of 5 stars$2.75-2.5%$32.33+1,075.8%N/A$38.09MN/A-0.57N/ATrending NewsAnalyst ForecastAnalyst RevisionGap DownXCURExicure1.9803 of 5 stars$5.89-0.5%N/A+198.1%$37.40M$500K-1.5250Positive NewsEPIXESSA Pharma3.069 of 5 stars$0.26-66.4%$2.00+660.2%-95.6%$37.08MN/A-0.4750Dividend AnnouncementOptions VolumeGap DownHigh Trading VolumeXLOXilio Therapeutics3.187 of 5 stars$0.700.0%$3.00+328.6%-12.9%$36.28M$6.34M-0.9270News CoveragePositive NewsESLAEstrella Immunopharma3.0838 of 5 stars$0.97+0.1%$16.00+1,550.3%-9.1%$35.92MN/A-3.73N/APositive NewsGap UpTHARTharimmune3.3943 of 5 stars$6.11-20.8%$17.00+178.2%+112.5%$35.74MN/A-1.002Gap UpMURAMural Oncology2.7081 of 5 stars$2.06flat$12.00+482.5%-36.8%$35.69MN/A-0.24119SCYXSCYNEXIS1.4836 of 5 stars$0.82-3.0%N/A-43.1%$35.43M$3.75M-2.0560 Related Companies and Tools Related Companies Medicus Pharma Alternatives Mersana Therapeutics Alternatives OnKure Therapeutics Alternatives Exicure Alternatives ESSA Pharma Alternatives Xilio Therapeutics Alternatives Estrella Immunopharma Alternatives Tharimmune Alternatives Mural Oncology Alternatives SCYNEXIS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNPX Stock Alerts